Skip to main content

Table 5 Relationship between clinical characteristics of NSCLC patients and treatment responses

From: Efficacy and safety of combined immunotherapy and antiangiogenic therapy for advanced non-small cell lung cancer: a real-world observation study

Characters

Case

CR

PR

SD

PD

χ2

p value

NSCLC

85

0

28

43

14

  

Gender

     

4.491

0.106

 Female

19

0

4

9

6

  

 Male

66

0

24

34

8

  

Age

     

2.169

0.338

 < 60

40

0

16

17

7

  

 ≥60

45

0

12

26

7

  

Brain metastasis

     

5.444

0.066

 No

63

0

21

35

7

  

 Yes

22

0

7

8

7

  

Liver metastasis

     

3.766

0.152

 No

70

0

24

37

9

  

 Yes

15

0

4

6

5

  

Bone metastasis

     

1.104

0.576

 No

52

0

19

24

9

  

 Yes

33

0

9

19

5

  

Pleural effusion

     

1.125

0.570

 No

71

0

25

36

40

  

 Yes

14

0

3

7

4

  

Smoke

     

2.635

0.268

 No

44

0

13

21

10

  

 Yes

41

0

15

22

4

  

Histology

     

3.806

0.149

 Adenocarcinoma

48

 

16

21

11

  

 Squamous cell carcinoma

37

 

12

22

3

  

Treatment line

     

8.504

0.075

 1 line

5

0

3

2

0

  

 2 lines

35

0

13

20

2

  

 ≥ 3 lines

45

0

12

21

12

  

PDL1 expression

     

22.123

0.000*

 Negative

44

0

8

29

7

  

 Low

28

0

9

14

5

  

 High

13

0

11

0

2

  

Gene mutation

     

10.636

0.100

 Wild

36

0

10

20

6

  

 EGFR

17

0

2

10

5

  

 KRAS

14

0

8

4

2

  

 Unknown

18

0

8

9

1

  

Adenocarcinoma

48

0

16

21

11

  

 PDL1 expression

     

14.032

0.007*

  Negative

26

0

5

15

6

  

  Low

12

0

3

6

3

  

  High

10

0

8

0

2

  

 Gene mutation

     

8.183

0.085

  Wild

19

0

6

8

5

  

  EGFR

16

0

2

9

5

  

  KRAS

13

0

8

4

1

  

Squamous cell carcinoma

37

0

12

22

3

  

 PD L1 expression

     

9.538

0.049*

  Negative

18

0

3

14

1

  

  Low

16

0

6

8

2

  

  High

3

0

3

0

0

  
  1. NSCLC Non-small cell lung cancer, CR Complete response, PR Partial response, SD Stable disease, PD Progressive disease. EGFR (epidermal growth factor receptor), including classical EGFR mutation and nonclassical EGFR mutation, KRAS, Kirsten Rat Sarcoma Viral Oncogene Homologue. PD-L1 (programmed death ligand 1) expression, Negative, 0%; Low, 1%-49%; High, ≥ 50%
  2. *significance p values